Sensorium Therapeutics Inc. has reported that the U.S. FDA has cleared the IND application for SNTX-2643 (SENS-01), its lead anxiety program. First-in-human dosing begins in Q3 2025.
Insightec Ltd. received U.S. FDA approval for use of its Exablate Neuro device to address severe motor symptoms in patients with Parkinson’s disease, offering a new option for patients who have not found adequate relief from medications. Exablate Neuro uses focused ultrasound to create lesions in the brain without requiring an incision or implant.
Acurex Biosciences Corp. has divulged fused quinone compounds acting as ferroptosis inhibitors reported to be useful for the treatment of mitochondrial disease.
Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.
Merck Sharp & Dohme LLC has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others.
Vanderbilt University has synthesized muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia and sleep disorders.
The oxidase, cytochrome c, assembly 1-like (OXA1L) gene plays a key role in inserting and assembling proteins in the inner mitochondrial membrane, and recent studies have linked some variants to mitochondrial encephalopathy. However, the exact disease mechanism and causal link remain unclear.
The U.K. Medicines and Healthcare Products Regulator Agency dropped a guidance for digital mental health technologies that clarifies several key points, such as when the DMHT qualifies as software as a medical device.
RSS
